iOMEDICO AG

PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant (2023) Degenhardt T, Fasching P, Lüftner D, Müller V, Thomssen C, Schem C, Witzel I, et al. Journal article Sarcopenia assessments as predictors of overall survival in patients with metastatic renal cell carcinoma (2023) Kümmerl L, Kraulich M, Lesyuk W, Binninger A, Goebell P, Kahlmeyer A Journal article Thrombospondin-2 and LDH: potential predictive biomarkers for the treatment of metastatic renal cell carcinoma with everolimus after one VEGF-targeted therapy (MARC-2 study) (2022) Zeuschner P, Hoelters S, Stoeckle M, Seliger B, Mueller A, Bachmann HS, Gruenwald V, et al. Conference contribution Sequential treatment patterns over time for advanced renal cell carcinoma: data from the German research platform CARAT (2022) Goebell P, Gruellich C, Mueller L, Boegemann M, Martens U, Von Der Heyde E, Reichert D, et al. Conference contribution Treatment of patients with advanced urothelial carcinoma in routine care in Germany: initial data from the CARAT-UBC cohort (2022) Goebell P, Mueller L, Boegemann M, Rauh J, Nusch A, Andres-Pons A, Hamm N, et al. Conference contribution Thrombospondin‐2 and ldh are putative predictive biomarkers for treatment with everolimus in second‐line metastatic clear cell renal cell carcinoma (Marc‐2 study) (2021) Zeuschner P, Hölters S, Stöckle M, Seliger B, Mueller A, Bachmann HS, Grünwald V, et al. Journal article Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial (2020) Staehler M, Stoeckle M, Christoph DC, Stenzl A, Potthoff K, Grimm MO, Klein D, et al. Journal article Reduction of Serious Adverse Events (SAE) under palbociclib treatment in patients using an interactive eHealth system (2020) Schmidt M, Degenhardt T, Fasching P, Lueftner D, Mueller V, Thomssen C, Schem C, et al. Conference contribution Reduction of Serious Adverse Events (SAE) under palbociclib treatment in patients using an interactive eHealth system (2020) Schmidt M, Degenhardt T, Fasching P, Lüftner D, Müller V, Thomssen C, Schem C, et al. Journal article First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial (2020) Staehler M, Panic A, Goebell P, Merling M, Potthoff K, Herrmann E, de Geeter P, et al. Journal article